Antiglutamate therapies in Huntington’s disease
Huntington’s disease is an autosomal dominant neurodegenerative disorder caused by an unstable trinucleotide CAG repeat. The mechanism by which the genetic defect leads to neuronal injury and death is unknown, but is thought to include glutamate-mediated excitotoxicity and abnormalities of mitochondrial energy production. Both of these mechanisms may lead to a final common pathway of increased production of free radical species. Prior clinical trials in patients with Huntington’s disease that have addressed these hypotheses have been limited by size. A current, NIH-funded trial of remacemide hydrochloride and Coenzyme Q10 in 340 patients with Huntington’s disease is described. This is the largest and longest multi-center trial in Huntington’s disease to address the glutamate- and mitochondrialmediated hypotheses of neurodegeneration.
KeywordsQuinolinic Acid Striatal Projection Neuron Total Functional Capacity Prior Clinical Trial Hopkins Verbal Learning Test
Unable to display preview. Download preview PDF.
- Beal W, Brouillet E, Jenkins BG, Ferrante RJ, Kowall NW, Miller JM, Storey E, Srivastava R, Rosen BR, Hyman BT (1993a) Neurochemical and histological characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 13: 4181–4192.PubMedGoogle Scholar
- Greenamyre JT, Shoulson I (1994) Huntington’s Disease. In: Calne DB (ed) Neurodegenerative disease. Saunders, Philadelphia, pp 685–704.Google Scholar
- Kremer B, Clark CM, Hardy M, Almqvist E, Raymond L, Hayden MR (1997) Lamotrigine does not retard the progression of Huntington’s disease. 17th International Meeting of the World Federation of Neurology Research Group on Huntington’s Disease 8/30-9/2/97 (abstract).Google Scholar
- Landwehrmeyer GB, Standaert DG, Testa CM, Penney JB, Young AB (1994) NMDA receptor subunit expression by rat striatal projection neurons and intemeurons. J Neurosci 14: 5297–5308.Google Scholar
- Penney JB Jr, Young AB, Shoulson I, Starosta-Rubenstein S, Snodgrass SR, Sanchez Ramos J, Ramos-Arroyo M, Gomez F, Penchaszadeh G, Alvir J, Esteves J, DeQuiroz I, Marsol N, Moreno H, Conneally PM, Bonilla E, Wexler NS (1990) Huntington’s disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals. Mov Disord 5: 93–99.PubMedCrossRefGoogle Scholar
- Reitan RM, Wolfson D (1958) The Halstead-Reitan Neuropsychological Test Batttery. Neuropsychology Press, Tucson.Google Scholar
- Shoulson I, Kurlan R, Rubin AJ, Goldblatt D, Behr J, Miller C, Kennedy J, Bamford KA, Caine ED, Kido DK, Plumb S, Odoroff C (1989a) Assessment of functional capacity in neurodegenerative movement disorders: Huntington’s disease as a prototype. In: Munsat TL (ed) Quantification of neurological deficit. Butterworths, Boston, pp 271–283.Google Scholar